Introduction
Since its discovery over 30 years ago, human immunodeficiency virus (HIV) has been one of the most widely studied viruses in medical history. Whilst much is known about how prognosis varies between patients, there is still a large proportion of this variance thus far unexplained [1, 2] . One potential means of explaining some of this variance comes from neuroimmune influences, and more specifically from hemispheric lateralisation (HL) and its effects on the immune system. HL refers to the relatively stable tendency to activate or rely on functions of one hemisphere more than the other [3, 4] . A recent review has suggested an immunopotentiating role for the left hemisphere and an immunosuppressant role for the right hemisphere in humans [5] . However, very little confounder control has been exerted in studies so far and therefore the HL-immune relationship requires substantiation with stricter methodological control, and exploration of mediating and moderating variables.
One study has examined the implications of HL on HIV prognosis by examining the longitudinal immune correlates of HL in HIV [6] . Gruzelier et al. [6] found that left HL was associated with better immune outcomes (CD4+/CD8+ T cells) at a 30-month follow-up. Further-more, their study also described a relatively poorer prognosis in patients with right HL. However, their sample was small (n = 26) and relatively uniform. Most importantly, they did not control for effects of baseline immune parameters and other confounders (e.g. mood, mode of infection or other illnesses) that may affect the central and autonomic nervous system or the course of HIV [7] . Additionally, the study did not selectively recruit righthanded participants, a measure which is central in HL research. Left-handed individuals characterise atypical interhemispheric communication and hemispheric specialisation [8, 9] . Finally, the research was conducted before the advent of HAART (highly active anti-retroviral therapy), one of the most significant developments in HIV medicine [10] . These limitations question the validity of their inferences, and the application of the findings to modern HIV patients and treatment.
The present study aimed to extend the findings of the Gruzelier group and examine the prospective relationship between HL and CD4+ T-cell counts in HIV-1+ patients with better methodological and statistical control. Methodologically, a larger sample of participants was sought from broader demographic profiles. Only righthanded participants were recruited to eliminate the heterogeneity observed in HL amongst left-handed and ambidextrous people. Additionally, strict exclusion factors were implemented to reduce confounders. Statistically, the influence of relevant confounders was tested as well. The present study also aimed to identify and evaluate potential variables that may moderate or mediate the relationship between HL and HIV prognosis. Identified a priori, mood; HAART medication status and adherence, and duration of HIV infection were selected as potential moderating or mediating variables due to their influence on immune status and trajectory in HIV disease [11, 12] . It was hypothesised that left HL would predict a better immune outcome in asymptomatic HIV patients.
Methods

Participants and Recruitment Criteria
The participant sample (n = 68) was drawn from a clinical population of HIV+ outpatients of a hospital located in Brussels, Belgium. Inclusion criteria for the study were: right-handedness; asymptomatic HIV-1 disease (CD4+ T-cell count >200/mm 3 ); good literacy and verbal fluency in Flemish, French or English; age between 18 and 80 years and no presence of cognitive deficits. Exclusion criteria were based on three research requirements: cognitive capability, extraneous modulation of HIV disease course and extraneous modulation of the communication between the brain and the immune system. Cognitive capability was ascertained by including patients scoring >25 on the Mini Mental State Examination (MMSE) [13] with candidates scoring <25 being excluded from further participation. Patients who had a diagnosis of any psychiatric illness were also excluded. Additionally, patients who were pregnant, had been diagnosed with a neurological disorder or autoimmune disease, or were either on immune-modulating (outside of HAART regimens) or autonomic nervous system-modulating drugs were excluded. Any patient who had a medical history of dependence/abuse of alcohol, methamphetamine or cocaine was excluded. Further, any medical history of clinically meaningful brain damage was another indicator for study exclusion.
Measures and Materials
HL was assessed using the hemispheric preference test (HPT) [14] and a computerised variant of the line bisection test (LBT) [15] using prebisected lines. The HPT includes 20 items, with 10 items reflecting either right or left characteristics (e.g. visualisation and strategic thinking, respectively). A 'left' index of the HPT was calculated using the formula: left HL = 100 × (left -right)/(left + right). In the LBT, participants estimated which side of a prebisected line was larger when both in fact were equal. Both tests have been validated against EEG measures of HL [16, 17] . CD4+ T-cell counts were obtained from the participants' medical files 3 months before study entry (T1), at study entry (T2) and 3 months later (T3). Mood was assessed using the Hospital Anxiety and Depression Scale [18] and adherence to HAART was measured using the Morisky Medication Adherence Scale [19] . Participants were also surveyed for their sociodemographic background, HIV-relevant history (e.g. mode of infection and time since diagnosis) and health behaviour (e.g. addictive substance use, condom use and number of sexual partners in the previous year).
Procedure
Data were collected over three time points (T1, T2 and T3). A retrospective medical baseline (T1) for T-cell data was adopted to have a longer follow-up between immune outcomes. At study entry (T2), participants were screened with the MMSE and given a semistructured interview for demographic information and adherence. Participants' HL was measured by the HPT and LBT at T2.
Follow-up data was collected approximately 3 months after study entry (T3).
Statistical Analysis
All data analyses were run using the calculated left HL index with a square root transformation (SQRT) of the scores (to normalise their distribution) and a corresponding left HL index of the LBT. Confounders in relation to CD4+ at T3 were assessed statistically from the available data using bivariate Pearson correlations for continuous data (e.g. age/time since diagnosis) and the t test or ANOVA for categorical data (e.g. ethnicity/mode of contraction). Those variables that presented significant (p < 0.05) associations with CD4+ at T3 were used as covariates in each multivariate correlation. Analyses were conducted using Spearman's ρ correlation in order to counteract bias due to outliers within the dataset. To ensure that confounding variables were still controlled for in the tests using Spearman's ρ, T3 CD4+ scores (dependent variable) were residualised on medication variables and/or on T1 CD4+ data, which emerged as the significant confounders. The relationship between left HL and these residualised CD4+ scores were then examined by Spearman's ρ correlations. Moderator analyses were Neuroimmunomodulation 2014;21:31-36 DOI: 10.1159/000355350 33 repeated using Spearman's ρ correlation, split by moderator subgroup (e.g. HAART/non-HAART). The statistical and clinical significance of these results was then tested using logistic regression where the dependent variable was a clinically significant cut-off of CD4+ outcome data. Participants' outcome (T3) CD4+ T-cell levels were categorised into high (CD4+ T-cell count >500/mm 3 ) or low (CD4+ T-cell count <350/mm 3 ) and analysed against the T1 CD4+ scores, use of HAART and left HL scores.
Results
Sample Characteristics
The original sample size was 72; 4 participants had to be excluded from final analyses due to comprehension problems (n = 3) and outlying HPT data (n = 1). Table 1 shows the summary composition of the study sample.
HL and Immunity in HIV
Among all confounders, only baseline (T1) CD4+ Tcell count and HAART were significantly associated with T3 CD4+, hence we controlled for their effects statistically. A Spearman's ρ correlation was conducted between the standardised prospective CD4+ T-cell measurement (CD4+ T3, residualised on CD4+ T1 and HAART medication as covariates) and SQRT HPT. There was a statistically significant correlation between left HL and outcome CD4+ T-cell count (ρ = 0.234, p = 0.047, one-tailed test, n = 61).
Moderator Analyses
. No significant difference was observed between outcome (T3) CD4+ counts for these two groups (t (58) = 1.75, p = 0.086). Spearman's ρ correlations were conducted between the standardised prospective CD4+ T-cell outcome measurement (CD4+ T3, residualised on CD4+ T1 and HAART medication) and the SQRT HPT as predictor split by ethnicity group. There were no statistically significant correlations between left HPT and outcome CD4+ T-cell count for the European subsample (ρ = 0.241, p = 0.081, one-tailed test, n = 35), though a trend was observed for the African subsample (ρ = 0.402, p = 0.055, one-tailed test, n = 17).
HAART Medication. A significant difference was observed between patients with and without HAART treatment in T3 CD4+ counts (t (50,80) = 2.06, p = 0.045), with those taking HAART having the higher levels of outcome T-cell counts. HAART was tested as a potential moderator in the HL-CD4 relationship due to its immunomodulating effects within HIV disease and the large proportion of participants (n = 48, 70.6%) reporting to be undergoing HAART treatment. Spearman's ρ correlations were conducted between the outcome CD4+ T-cell measurement (CD4+ T3 residualised on CD4+ T1) and SQRT HPT as predictor split by treatment group. There was no statistically significant correlation between left HPT scores and outcome CD4+ T-cell count for the HAART-treated subsample (ρ = 0.153, p = 0.170, one-tailed test, n = 41). In contrast, there was a statistically significant correlation between left HPT scores and outcome CD4+ in the non-HAART group (ρ = 0.627, p = 0.019, one-tailed test, n = 11; fig. 1 ). 
Does HL Predict Clinically Significant Outcome CD4+?
In order to explore whether the clinical categorisation of T3 (outcome) CD4+ T-cell count (high = CD4+ >500/ mm 3 ; low = CD4+ <350/mm 3 ) is influenced by left HL (controlling for baseline CD4+ T-cell count and HAART medication status), a binary logistic regression model was performed. The results from the logistic regression are presented in table 2 and show that both T1 CD4+ T-cell count and left-HL (SQRT HPT) scores significantly predicted the clinically significant categorisation of CD4+ Tcell levels at T3.
Additionally, we tested for an interaction between HAART and left HL with either a linear regression for the continuous outcome CD4+ (T3) or a logistic regression for the categorical outcome of high versus low CD4+. Both regressions testing this interaction were non-significant (p > 0.05). Concerning the regression of the categorical CD4+ levels, analysis of the cells of the interaction provided very small sample sizes for the non-HAARTtreated subgroup (low CD4+ n = 5; high CD4+ n = 4) against the HAART-treated subgroup (low CD4+ n = 11; high CD4+ n = 28). Thus, while formally HAART did not significantly interact with HL in predicting CD4+ levels, HAART did emerge as a moderating variable as revealed in the analyses mentioned above.
Discussion
HL Predicts CD4+ T-Cell Count
The present study sought to examine the predictive ability of HL in relation to prognosis in HIV-1+ patients. The main finding showed a significant, positive relationship between left HL and CD4+ T-cell count at 3 months. The measure of HL which predicted follow-up CD4+ levels was a standardised questionnaire validated against an EEG. This finding, albeit relatively modest, is in line with those found in a previous HIV+ patient sample [6] and amongst the wider literature describing a relationship between left HL and enhanced immunity [5] . Further, the logistic regression uncovers a clinically significant relationship between outcome CD4+ T-cell count categories (high vs. low) and left HL, controlling for confounders. This finding suggests that HL could serve as a clinical predictor of CD4+ T-cell loss trajectory, and therefore an indicator of potential intervention both possibly determined by HL and targeting HL.
Moderation
The analysis for moderation by ethnicity did not attain statistical significance, however, a trend was indicated. In contrast, the analysis for moderation by medication group revealed a significant, positive relationship between left HL and CD4 levels at follow-up only in those patients who were not receiving antiretroviral treatment. This analysis indicated that approximately 39.3% of the variance observed in follow-up CD4+ levels could be at- tributed to left HL, controlling for baseline CD4+ counts.
These new findings present a new dimension to the current knowledge on HL in HIV disease, for which the effect size is clinically significant. However, this result must be taken with caution since HAART status did not significantly interact with HL in relation to both continuous and categorical CD4+ outcomes. It is possible that this lack of support from these tests may be attributable to insufficient data in one or more of the cells of the interaction. We nevertheless examined and found a possible moderating role for HAART status, which would otherwise not have been revealed (a type-2 error). Yet, these findings need to be replicated in a larger sample. Why left HL may be predictive of CD4+ outcome in treatment-naïve patients, but not HAART-treated patients, is not clear. It is possible that if both left HL and HAART are working in unison toward immunopotentiation, the effects of HL in the presence of HAART may be masked. This explanation is partially substantiated when examining other immune cells affected in the same way by HL and HIV. For example, induction of HAART treatment has been shown to affect (amongst others) lymphocyte proliferation and neutrophil function [20, 21] . These immune measures have also been demonstrated to be asymmetrically influenced by HL [22, 23] . It is possible that lacking HAART enables HL to manifest its immunomodulatory effects, which is manifested in our results by the strong HL-CD4+ correlation in non-HAART patients. Should this finding be replicated, it may have vast implications for countries where access to HAART is limited, since activating the left hemisphere can enhance immunity [24] .
Limitations
The sample size of the present study was restricted due to missing data, and the variables of the dataset were still skewed even after data transformation. Further, the subsample groups were not equal in type or composition. As HAART was used as a moderating variable, control based on specific line and type of HAART treatment may further elucidate these findings. The period of follow-up was significantly shorter ( ≈ 6 months) than the 30-month follow-up employed by Gruzelier et al. [6] . Finally, the HL assessments themselves were a deviation from the precedent of EEG employed by Gruzelier et al. [6] , although the measures were also validated by EEG. Nevertheless, our results support the HL-immune relationships reviewed recently [5] and extend them to HIV with more rigorous methodology. Despite these limitations, the observed HL-CD4+ relationship was found both for continuous levels and clinically significant levels of CD4+ independent of confounders.
Future Directions
Further assessment of this relationship within the HIV context is required, most specifically the potential moderating implication of ethnicity and HAART. Analysis of the quality of moderation by HAART may also provide useful information (i.e. first-or second-line treatments/types of medication). Should more empirical evidence support the role of HL in HIV prognosis, targeted interventions can be devised at relatively low costs with high mobility to reach those areas still under a heavy HIV burden. These include testing whether activating the left hemisphere, e.g. by focused (and free) cognitive exercises that activate that hemisphere, could possibly affect CD4+ levels in patients not receiving HAART.
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